---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-020146"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2024-02-26T23:59:59+00:00"
generated_at: "2026-06-05T16:21:30.095617+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# FibroGen FY23 rev $147.8M (+5% YoY), net loss $284.2M; guides China roxadustat $300-340M

## Summary
- Full year 2023 total revenue $147.8M, up 5% YoY; net loss $284.2M ($2.92 per share), narrower than $293.7M loss in 2022.
- Roxadustat net sales in China (FibroGen share) $100.9M in FY23, up 22% YoY; total China sales including JDE $284.1M (+36% YoY) driven by 41% volume growth.
- Cash and equivalents $248.1M, with runway into 2026 after $120M annual cost reduction.
- Pipeline: topline data from two pamrevlumab pancreatic cancer trials expected in 2Q 2024; Phase 1 FG-3246 data in mCRPC in 1Q 2024.
- Guidance: FY 2024 FibroGen net product revenue $120-135M; total roxadustat China sales $300-340M; potential CIA approval in China mid-2024 with $10M milestone.

## SEC filing metadata
- accession: 0000950170-24-020146
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2024-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017024020146/0000950170-24-020146-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017024020146/fgen-20240226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-020146
- JSON: https://secwatch.observer/filing/0000950170-24-020146.json
- Plain text: https://secwatch.observer/filing/0000950170-24-020146.txt

## Key facts
- Earnings Releases
  KYNTRA BIO, INC. reported year ended December 31, 2023 results: revenue $147.8 million, net income Net loss for the year was $284.2 million, or $2.92 net loss per basic and diluted share, EPS $2.92 net loss per basic and diluted share.
  - Period: year ended December 31, 2023
  - Revenue: $147.8 million
  - Net income: Net loss for the year was $284.2 million, or $2.92 net loss per basic and diluted share
  - EPS: $2.92 net loss per basic and diluted share
  - Result: reported results
  source text: 2024 • FibroGen regains rights to roxadustat from AstraZeneca in the United States and other AstraZeneca territories, except China and South Korea • FY 2023 total net revenue of $147.8 million, an increase of 5% year over year • Robust roxadustat volume growth of 41% in China in FY 2023 compared to FY 2022 • Successful execution of cost reduction plan; $248.1 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000095017024020146/0000950170-24-020146-index.htm
- Earnings Releases
  KYNTRA BIO, INC. reported quarter ended December 31, 2023 results: revenue $27.1 million, net income Net loss for the fourth quarter of 2023 was $56.2 million, or $0.57 net loss per basic and diluted share, EPS $0.57 net loss per basic and diluted share.
  - Period: quarter ended December 31, 2023
  - Revenue: $27.1 million
  - Net income: Net loss for the fourth quarter of 2023 was $56.2 million, or $0.57 net loss per basic and diluted share
  - EPS: $0.57 net loss per basic and diluted share
  - Result: reported results
  source text: full year roxadustat net sales in China 1 by FibroGen and the JDE to range between $300 million to $340 million. Financial: • Total revenue for the fourth quarter of 2023 was $27.1 million, as compared to $34.4 million for the fourth quarter of 2022. Reduction primarily driven by the change in net product revenue assumptions under U.S. GAAP and drug product revenue
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000095017024020146/0000950170-24-020146-index.htm
- Earnings Releases
  KYNTRA BIO, INC. reported 2024 results: revenue between $120 million to $135 million. Guidance reaffirmed.
  - Period: 2024
  - Revenue: between $120 million to $135 million
  - Guidance: reaffirmed
  - Result: guidance update
  source text: For 2024, we anticipate FibroGen’s full year net product revenue under U.S. GAAP to range between $120 million to $135 million, representing full year roxadustat net sales in China 1 by FibroGen and the JDE to range between $300 million to $340 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000095017024020146/0000950170-24-020146-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.